Navigation Links
Thomas Jefferson University Kimmel Cancer Center: Researchers Find New Clues to Treat Rare and Aggressive Inflammatory Breast Cancer
Date:8/7/2013

(PRWEB) August 07, 2013

A study led by investigators from Thomas Jefferson University’s Kimmel Cancer Center has discovered molecular clues that may help physicians therapeutically target inflammatory breast cancer (IBC), a highly aggressive form of breast cancer.

Their study, reported in the June 21 online issue of Breast Cancer Research and Treatment, identified two molecules (ALK and FAK1) involved in the IBC cancer pathway. Drugs already exist that inhibit both of these two cancer-promoting proteins at the same time, which the researchers are now testing in animal preclinical studies.

“Women diagnosed with inflammatory breast cancer are in great need of therapies that are tailored to this aggressive form of breast cancer. Survival rates are much lower than for other forms of breast cancer,” says the study’s lead author Sandra V. Fernandez, Ph.D., Assistant Professor in the Medical Oncology department at Jefferson.

IBC is a particularly aggressive and highly metastatic form of breast cancer characterized by very rapid onset of progression— weeks to a few months — and metastasis that spreads quickly to the brain, bones, and soft tissues. The three-year survival rate is 40 percent for IBC patients compared with 85 percent in other forms of breast cancer. Additionally, IBC patients are younger when diagnosed.

The disease is also difficult to diagnose because it appears as redness and swelling of the breast. There are no classic tumor masses.

“Because of how this cancer looks, physicians often think it is dermatitis, or inflammation, or an infection, such as mastitis. I know of many patients who were misdiagnosed from the start, and by the time they were referred to an oncologist, their cancer had progressed,” says the study’s senior investigator, Massimo Cristofanilli, MD, FACP, Professor of Medical Oncology and Director of the Jefferson Breast Care Center.

“We need to improve both diagnosis and treatment of this cancer, which is on the rise for reasons that are not understood,” he says.

The advances reported in the study were possible because the research team developed a new animal model of IBC, derived from tumor cells from a patient with metastatic triple negative (estrogen receptor-negative, progesterone receptor-negative, Her2-negative) inflammatory breast cancer under an IRB-approved study. At the present, there are few animal models to study this particular disease.

In addition to identifying some of the pathways involved in IBC, the researchers were able to characterize the pattern of spread of the disease, which moved quickly to organs and the brain. They found that clumps of the cancer — not tumor masses — obstruct lymphatic channels in the breast, causing the swelling of breast tissues.

“This animal model is a really important tool to use to study IBC progression and metastasis, and to test potentially beneficial drugs,” says Dr. Fernandez.

Researchers from the University of Texas M D Anderson Cancer Center and Fox Chase Cancer Center contributed to the research.

The study was supported by the American Airlines-Komen for the Cure Foundation Promise Grant KGO81287, NIH NCI 1R01 CA 138239, and the In?ammatory Breast Cancer Foundation.

The authors declare that they have no conflicts of interest.

Thomas Jefferson University (TJU), the largest freestanding academic medical center in Philadelphia, is nationally renowned for medical and health sciences education and innovative research. Founded in 1824, TJU includes Jefferson Medical College (JMC), one of the largest private medical schools in the country and ranked among the nation’s best medical schools by U.S. News & World Report, and the Jefferson Schools of Nursing, Pharmacy, Health Professions, Population Health and the Graduate School of Biomedical Sciences. Jefferson University Physicians is TJU’s multi-specialty physician practice consisting of the full-time faculty of JMC. Thomas Jefferson University partners with its clinical affiliate, Thomas Jefferson University Hospitals.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11003953.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Katherine A. High, M.D., to present 2013 American Society of Hematology E. Donnall Thomas Lecture
2. Thomas the Train Lights and Sounds Trike Reviews Now Available at TricyleKids.com
3. Hollywood Comes to Thomasville North Carolina’s Favorite Restaurant -Southern Sisters
4. Thomas Hoey of Long Island Banana Corp. Defends Nutritional Quality of Fruit
5. The Law Offices of Michael Córdova Welcomes Meghann L. St. Thomas
6. Stephen K. Klasko, M.D., M.B.A., Named President of Thomas Jefferson University and President and CEO of TJUH System
7. Thomas Coleman's Tinnitus Miracle Treatment Review Discloses Alternative Natural Cure
8. Dr. Thomas P. McHugh Receives 2013 Best of The Woodlands Award
9. Thomas Miller Mortuary Announces The Launch Of The New Cremation Society of Southern California
10. Lewis Thomas Prize to be awarded to Kay Redfield Jamison
11. Thomas Miller Mortuary Expands Their Services With The Cremation Society of Southern California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many ... reviews available that integrate basic science with clinical practice. Now, however, a timely review ... providing clinicians with insight into the etiology of NeuP and educating preclinical scientists on ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... A June ... Rittenberg to a correspondent concerned about an apparent lack of oral hygiene by an ... specializes in geriatrics and dementia-related matters, suggests a number of steps, including scheduling a ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... CHRISTUS Health, a Texas-based health system, will present how predictive analytics drive reimbursement ... HFMA ANI meeting in Orlando, June 25-28. , “The traditional approach to ...
(Date:6/20/2017)... Gainesville, FL (PRWEB) , ... June 20, 2017 ... ... interactive health science curriculum , is pleased to announce a new online ... The accredited online course provides practical insights and evidence-based strategies for achieving optimal ...
(Date:6/20/2017)... ... ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the ... JIAS Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among his ... and Co-Chair of The Fenway Institute, a member of the US President’s Emergency Plan ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... location. The Iowa facility ... cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A cleanroom ... "Our new cleanroom will allow us ... Iowa patients," said Phil Rielly , Diplomat ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)...  Endo International plc (NASDAQ: ENDP ) announced ... represent the Company in a fireside chat at Goldman Sachs, ... 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ET. ... Rancho Palos Verdes, CA. A ... available on the Company,s website at http://www.endo.com/investors/overview . Participants ...
Breaking Medicine Technology: